ARTICLE | Clinical News
PRO-513: Phase III started
May 29, 2006 7:00 AM UTC
ProEthic Pharmaceuticals Inc., Montgomery, Ala. Product: PRO-513 Business: Neurology Molecular target: Cyclooxygenases (COX) Description: Oral formulation of diclofenac potassium powder utilizing Dy...